Europe Infusion Therapy Market - 2023-2030

Europe Infusion Therapy Market - 2023-2030

Market Overview
The Europe Infusion Therapy market size was valued at US$ 11,069.73 million in 2022 and is estimated to reach US$ 19,152.54 million by 2030, growing at a CAGR of 7.2% during the forecast period (2023-2030).

Infusion therapy is a therapeutic procedure that delivers the medication through sterile needles and catheters through other non-oral routes, such as intramuscular injections and epidural routes. Medical conditions requiring infusion therapy include infections and diseases that may not be responsive to oral antibiotics, such as Cancer and cancer-related drugs, dehydration, and gastrointestinal diseases or disorders.

An infusion therapy provider is most normally a ""closed-door,"" state-licensed pharmacy that specializes in providing infusion therapies to patients in their homes or other alternate sites called home infusion therapy pharmacy. Home infusion therapy is a comprehensive service that provides safe and effective administration of parenteral prescription medications and biologics in a patient's home or other alternate sites.

Market Dynamics
The major factors driving the Europe Infusion Therapy market are the high prevalence of Cancer propelling infusion therapy market, favourable government policies and regulations are expected to propel market growth.

High prevalence of Cancer is expected to drive the market’s growth.
Infusion therapy is frequently used to provide chemotherapy, immunotherapy, and targeted therapy to treat Cancer. The catheter is a tiny, flexible tube used in infusion therapy that transports fluids into a patient's body through a vein. The fluids are normally administered from a plastic bag holding medication.

Cancer illnesses are prevalent, which is increasing the need for infusion therapy. Europe is an important focus for compiling accurate and up-to-date world cancer statistics owing to its large share of the world's total cancer burden.

For instance, according to the European Journal of Cancer, the estimated national incidence and mortality rates are computed using statistical methods that have been applied and validated using the most recent incidence data from 151 population-based cancer registries, death data, and 2020 population estimates. Estimates show 1.9 million cancer-related deaths and 4 million new cases of Cancer (excluding non-melanoma skin cancer). The most prevalent malignancies are prostate (580,000 cases), colorectal (520,000), lung (480,000), and breast (530,000 cases) in women (470,000). Half of all cancer cases in Europe are caused by these four diseases. Lung (380,000), colorectal (250,000), breast (140,000), and pancreatic cancers are the most frequent causes of cancer-related deaths. In the EU-27, there are an anticipated 1.4 million new cases of Cancer in men and 1.2 million in women, with around 710,000 men and 560,000 women expected to die from the disease. The market is being driven by the growth in infusion therapies brought on by the rise in the prevalence of certain disorders.

Side effects of the procedure will expected to hamper the market’s growth.
However, in contrast, complications related to medicine delivery, irregularities in how infusion therapy works, and complicated reimbursement procedures may restrain market expansion. Specific infusion therapies may impact the patient's capacity for conception and reproduction. Both men and women can use this. Depending on the specific treatment plan—including the type of treatment, the dosage, and how long it lasts—a patient's fertility may be at risk.

COVID-19 Impact Analysis
The spreading COVID-19 epidemic is predicted to open up attractive investment prospects. Due to COVID-19's limitations, patients delay treatment until they feel secure. Using alternate site solutions became increasingly popular in 2020 as COVID-19 cases grew, and specialized infusion providers were crucial in helping patients.

Additionally, many patients who get infusion therapy already have illnesses that impair their immune systems over time. Going outside even to receive treatment in such circumstances poses a risk. Even if patients decide to continue their treatment, shortened business hours have made it difficult to find available times for appointments. Infusion therapy is therefore anticipated to be essential in helping patients. Due to the fast urbanization and growing need for efficient use of space, the sector anticipates many needs and demands following the pandemic.

Segment Analysis
The chemotherapy segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)
The application segment is the highest market holder in the Europe infusion therapy market. The factors for the growth of the chemotherapy segment are the technological advancements and key player partnerships, product approvals and new product launches in the region. For instance, in December 2022, Imfinzi (durvalumab) from AstraZeneca received approval in the European Union (EU) for the first-line chemotherapy-plus-durvalumab treatment of adult patients with metastatic or unresectable biliary tract cancer (BTC) (gemcitabine plus cisplatin). The primary results from the TOPAZ-1 Phase III study, published in the New England Journal of Medicine Evidence, and the updated results, presented at the European Society for Medical Oncology Congress 2022, served as the foundation for the European Commission's approval. The clearance comes after the European Medicines Agency's Committee for Medicinal Products for Human Use recommended it in November 2022.
Additionally, in December 2022, The European Commission (EC) approved the targeted radioligand therapy Pluvicto (INN: lutetium (177Lu) vipivotide tetraxetan), according to Novartis. Pluvicto is approved for use in conjunction with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC)3. These patients received a chemotherapy regimen based on taxanes.

Geographical Analysis
Germany holds the largest market share in the Europe Infusion Therapy market.

Germany dominates the Europe Infusion Therapy market primarily due to its large population, excellent medical infrastructure, and high-income levels. Germany dominates the market due to the rise in the prevalence of chronic diseases like heart disease, Cancer, diabetes and others in the country.

For instance, according to the latest WHO data published in 2020, Coronary Heart Disease Deaths in Germany reached 147,055 or 20.98% of total deaths. The age-adjusted Death Rate is 56.09 per 100,000 population, ranking Germany 155 worldwide. And according to The Organization for Economic Co-operation and Development (OECD), In comparison to other EU nations, Germany spends more per person on health care, offering a wide range of benefits, a high level of service delivery, and good access to care. However, the system's fragmentation across various payers and providers causes inefficiencies and a decline in the quality of care in some care settings, which is frequently reflected in average health outcomes.

Germany spent the most on health care per person, at EUR 4 300 (11.2 percent of GDP), approximately 1400 euros more than the EU average of EUR 2 884. Germany also boasts among the greatest bed, physician, and nurse densities per capita in the EU.

Competitive Landscape
The Infusion Therapy market is moderately competitive with local and Europe companies’ presence. Baxter International Inc., Johnson & Johnson, Braun Melsungen AG, ICU Medical, Inc., Allergan plc., Fresenius SE & CO. KGaA, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Hoffmann-La Roche Ltd., Celgene Corporation. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in May 2021, 2021, The European Commission (EC) has approved the use of VENCLYXTO (venetoclax) in combination with a hypomethylating drug, such as azacitidine or decitabine, to treat adult patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intense chemotherapy.
Baxter International Inc.

Overview: The Company Baxter International Inc. (Baxter) offers a variety of medical supplies. Its product and service offerings include sterile intravenous solutions, generic injectable medications, parenteral nutrition therapy, infusion systems and devices, inhaled anesthetics, surgical hemostat and sealant products, as well as dialysis for both acute and chronic illnesses. Hospitals, rehabilitation facilities, kidney dialysis clinics, nursing homes, and patients' homes all use the company's products. Baxter distributes its goods through a network of independent distributors, medication wholesalers, specialty pharmacies, and other providers of alternate sites in addition to its own direct sales staff. In addition to the Americas, the Middle East, Africa, Europe, and Asia-Pacific, the corporation operates in these regions.

Product Portfolio
IV Solutions: The 0.9% Sodium Chloride Injection, USP in both Viaflex Container and Viaflo Container (non-PVC, non-DEHP). 5% Dextrose Injection, USP in both Viaflex Container and Viaflo Container (non-PVC, non-DEHP). Lactated Ringer’s Injection, USP.

The Europe Infusion Therapy market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.